Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YL 13027

Next Previous
Drug Profile

YL 13027

Alternative Names: YL-13027

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Yingli Pharmaceutical
  • Developer 280Bio; Shanghai Yingli Pharmaceutical; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Pancreatic cancer
  • No development reported Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 15 Sep 2025 M.D. Anderson Cancer Center in collaboration with 280Bio terminates a phase-Ib trial in Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA due to less than 75% participation in the trial (NCT06199466)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
  • 29 Oct 2024 Shanghai YingLi Pharmaceutical plans a phase I/II trial for Pancreatic cancer (Metastatic disease) in November 2024 (PO) (NCT06662669)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top